| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.12 | 0.5 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |